We are thrilled to announce that our compound, NT102, has received FDA Rare Pediatric Disease Designation! This designation recognizes our commitment to addressing critical unmet needs for children with Dravet Syndrome. This milestone brings us one step closer to making a difference in the lives of patients and their families. #dravetsyndrome #epilepsy #mitochondria #PediatricHealth #RareDisease
Neuroene Therapeutics
生物技术研究
Washington,District of Columbia 246 位关注者
Developing mitochondrial small molecule drugs for difficult to treat neurological diseases.
关于我们
Developing mitochondrial small molecule drugs for difficult to treat neurological diseases.
- 网站
-
https://www.NeuroeneTherapeutics.com
Neuroene Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Washington,District of Columbia
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Parkinson's Disease、Mitochondria、Dravet Syndrome和Epilepsy
地点
-
主要
7144 13th Pl NW
US,District of Columbia,Washington,20012
Neuroene Therapeutics员工
动态
-
A full house at the Michael J. Fox Foundation 2024 Parkinson's Disease Therapeutics Conference in NYC! Looking forward to meeting everyone and learning about the latest in the pipeline. #parkinsonsdisease #mitochondria #mjff
-
We're at the BioHealth Capital Region Forum this week at the US Pharmacopeia. Beautiful space, great speakers (including two Governors, Montgomery County executive, major Pharma, university leaders and many others)! We'll be pitching on Thursday for the Investor Conference portion of this meeting. See you there! #epilepsy #parkinsonsdisease #raredisease #mitochondria
-
Sherine Chan, co-founder and CEO of Neuroene Therapeutics, shares how Neuroene's small molecule compounds support mitochondrial health to target neurological diseases like epilepsy. Follow along this week as we share more stories of #SmallMoleculesBigVoices from scientists, patient advocates, and policymakers.
-
Fantastic news for Neuroene Therapeutics! We are excited to announce that Neuroene is the Emerging Company Winner of Biotechnology Innovation Organization's Start-Up Stadium Pitch Contest at the 2024 BIO International Convention! Thank you to the judges and to all who attended our pitch - your enthusiasm for our mitochondrial therapeutics for epilepsy, Parkinson's disease and mitochondrial diseases gives us validation and further motivation to get to the clinic as fast as possible - the patients are waiting! Thanks to J.P. Carroll for a great write-up! https://lnkd.in/ecmec9Vf #BIO2024 #BIO #epilepsy #parkinsonsdisease #parkinsons #dravetsyndrome #mitochondria #mitochondrialdisease #neuroene
-
What an amazing #BIO2024! Grateful for Neuroene Therapeutics' QuickFire Challenge award from #BLUEKNIGHT and to BIO for organizing fantastic events. Had productive partnership meetings at the business forum and after-hours receptions. Startup Stadium was a blast to pitch at, and thank you to all who attended to hear about our work and for those who connected afterward. It was a pleasure meeting new friends and reconnecting with old ones. Special thanks to Natalie J. Galant, PhD for the arm pose tutorial :) #epilepsy #parkinsonsdisease #mitochondria
-
We are thrilled to be announced as one of the awardees for the hashtag #BLUEKNIGHT #QuickFireChallenge. Inspired to continue innovating for a better and safer future. #neuroene #epiloid #epilepsy #parkinsonsdisease #mitochondria
Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), launched the BLUE KNIGHT? Resident QuickFire Challenge: Partnering for Preparedness to propel resident companies to crucial inflection points in the commercialization process. We are proud to share the awardees of the QFC! Congratulations to Acclinate, Avecris, Decoy Therapeutics, Jurata Thin Film, Immunyx Pharma (partnering w/ Akagera Medicines, Inc) and Neuroene Therapeutics?(partnering w/ Epiloid Biotechnology) Their relentless pursuit of new innovations to protect us all against health security threats is inspiring! To learn more about Blue Knight: https://lnkd.in/gnF2_K_r